The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients

What Was Tested

The paper reports a study of Insulin Lispro, published as a randomized controlled trial.

Unmodified regular insulin has a long absorption tail, unlike the fast-acting insulin analog lispro, and may contribute to hypoglycemia in the early part of the night.

A randomized crossover double-blind study was performed to compare blood glucose concentrations in the early part of the night in type 1 diabetic patients receiving lispro or unmodified regular human insulin, in random order, on 2 separate study days.

Who Took Part

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The participants were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Insulin Lispro, so expectations could not easily colour the readings.

In the crossover set-up each of the participants took both Insulin Lispro and the comparison in turn, acting as their own control.

Identical meals and snacks were eaten at the same time during both study days.

What Was Measured

The subject headings attached to it are Blood Glucose, C-Peptide, Circadian Rhythm, Diabetes Mellitus, Type 1, Eating, Fasting and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Lispro.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Diabetes care), a journal based in United States.

More context: the Insulin Lispro compound page, all human trials.